Several possible studies
Story checked
Long‑acting medicines could make daily tablets a thing of the past for some patients (opens in a new tab)
medicalxpress.com · 2026-09-30
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Long‑acting medicines could make daily tablets a thing of the past for some patients
medicalxpress.com · 2026-09-30
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Cited as backgroundmentioned without context
How Missed Doses of Antibiotics Affect Bacteria Growth Dynamics.
Bulletin of Mathematical Biology · 2025
- Cited as backgroundmentioned without context
Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers
Journal of Viral Hepatitis · 2024
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedLong-acting medicines could make daily tablets a thing of the past for some patients by allowing treatment to be taken only once a month, every few months, or twice a year.View evidenceHide evidence
As statedonce a month, every few months or even twice a year
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedLong-acting medicines are designed to release a drug gradually into the bloodstream, which could make treatment easier to manage and reduce the risk of missed doses.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedIn HIV prevention, long-acting cabotegravir injections are available or recommended for some people at high risk of HIV who are unable to take daily oral PrEP, with dosing every two months after the initial doses.View evidenceHide evidence
As statedevery two months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedFor HIV treatment, cabotegravir combined with rilpivirine can be given as injections every two months instead of daily tablets for some people whose HIV is already well controlled.View evidenceHide evidence
As statedevery two months instead of daily tablets
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedThe article says more recent research has found that long-acting injectable treatment can improve viral control among some people who struggle to take daily HIV medication consistently.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedThe article says global research found many health care providers are willing to prescribe effective long-acting medicines, and patients have shown high interest in them as an alternative to tablets.View evidenceHide evidence
As statedmany ... willing; high interest
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedLong-acting medicines may not suit everyone because some people prefer tablets, and cost, access to clinics, and follow-up appointments can affect practicality.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 17 candidate papers
How Missed Doses of Antibiotics Affect Bacteria Growth Dynamics.
Bulletin of Mathematical Biology · 2025 · PubMed
Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers
Journal of Viral Hepatitis · 2024 · Crossref
HIV therapeutics in 2026.
Clinical Microbiology Reviews · 2026 · PubMed
Comparable Adherence and Viral Suppression Among Youth with Vertically and Horizontally Acquired HIV Receiving Cabotegravir–Rilpivirine with Specialty Pharmacy Support
Journal of AIDS and HIV Treatment · 2026 · Crossref
Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state.
Journal of Pharmacokinetics and Pharmacodynamics · 2026 · PubMed, Europe PMC
And 12 more candidates considered.